Table 1.
Demographic data of patients receiving combined anti–PD-1 and anti–CTLA-4 therapy
| Age, y | Gender | Malignancy | Therapy | TSH
|
Free T4
|
Free T3
|
TPO | TSI | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | Thyrotoxicosis | Hypo | B | Thyrotoxicosis | Hypo | B | Thyrotoxicosis | Hypo | |||||||
| 1 | 58 | F | Bladder ca. | Ipi + Nivo | 1.81 | 0.03 | x | 1.2 | 4.5 | x | 3.2 | 7.4 | x | x | x |
| 2 | 61 | M | Bladder ca. | Ipi + Nivo | 0.58 | 0.02 | x | x | 2.1 | x | x | x | x | x | x |
| 3 | 58 | M | Esophageal ca. | Ipi + Nivo | 2.03 | 0.02 | 32.6 | 1.3 | >5.9 | 0.5 | x | x | x | x | x |
| 4 | 72 | F | Melanoma | Ipi + Nivo | 2.79 | 0.03 | 45.48 | 1.3 | 4.9 | <0.3 | 3.2 | 7.8 | 1.8 | x | x |
| 5 | 49 | F | Melanoma | Ipi + Nivo | 0.84 | 0.2 | 12.46 | 0.9 | 1.5 | 0.6 | 2.5 | 4.1 | 1.9 | x | x |
| 6 | 72 | F | Melanoma | Ipi + Nivo | 1.27 | 0.03 | 45.48 | 1.3 | 4.9 | <0.3 | 2.8 | 7.8 | 1.8 | x | x |
| 7 | 51 | F | Melanoma | Ipi + Nivo | 0.48 | 0.01 | 55.77 | 1.4 | 1.3 | <0.3 | x | x | x | x | x |
| 8 | 36 | F | Melanoma | Ipi + Nivo | 0.7 | 0.02 | x | 1.2 | 2.4 | x | x | x | x | x | x |
| 9 | 66 | F | Melanoma | Ipi + Nivo | 0.48 | 0.04 | x | 1.2 | 2 | x | 3.1 | 3.6 | x | x | x |
| 10 | 53 | F | Melanoma | Ipi + Nivo | 1.68 | x | 7.28 | 1.1 | x | 0.5 | 3.1 | x | 2.2 | x | x |
| 11 | 64 | F | Melanoma | Ipi + Nivo | 2.39 | 0.03 | 9.23 | 1.2 | 2.8 | 0.7 | 2.7 | 5.9 | x | x | x |
| 12 | 67 | F | Melanoma | Ipi + Nivo | 3.42 | 0.01 | 9.51 | 1 | 4.6 | 0.4 | 2.6 | x | 1.5 | x | x |
| 13 | 66 | F | Melanoma | Ipi + Nivo | x | 0.02 | 8.12 | n/a | 3.5 | 0.6 | x | x | x | x | x |
| 14 | 52 | M | Melanoma | Ipi + Nivo | 3.2 | 0.05 | 9.91 | 1.1 | 1.6 | 0.6 | 3.5 | 4.5 | 3.1 | 10.8 | x |
| 15 | 44 | M | Melanoma | Ipi + Nivo | 1.3 | 0.02 | 5.66 | 1.4 | 5.4 | 0.8 | 3.4 | 8.2 | 2.3 | x | x |
| 16 | 47 | M | Melanoma | Ipi + Nivo | 3.36 | 0.04 | 69.76 | 1 | 2 | <0.3 | 2.8 | 3.7 | 1.5 | x | x |
| 17 | 69 | M | Melanoma | Ipi + Nivo | 2.16 | 0.02 | 18.9 | 1.4 | >5.9 | 4.2 | 2.7 | 15.1 | x | 17.1 | <1 |
| 18 | 25 | M | Melanoma | Ipi + Nivo | 1.14 | 0.02 | x | 1.1 | 2.7 | x | 3.5 | 6.5 | x | x | x |
| 19 | 53 | M | Melanoma | Ipi + Nivo | 4.33 | 0.07 | 9.91 | 1 | 1.6 | 0.6 | 3 | x | 3.1 | 10.8 | <1 |
| 20 | 78 | M | Melanoma | Ipi + Nivo | 3.76 | x | 28.67 | 1.1 | x | <0.3 | x | x | 1.4 | 398 | x |
| 21 | 47 | M | Melanoma | Ipi + Nivo | 3.36 | 0.04 | 69.76 | 1 | 2 | <0.3 | 2.8 | 3.7 | 1.5 | x | x |
| 22 | 64 | M | Melanoma | Ipi + Nivo | 0.89 | 0.02 | 54 | 1.1 | 6.3 | <0.3 | x | x | x | x | x |
| 23 | 58 | M | Melanoma | Ipi + nivo | 2.44 | 0.02 | x | 1.4 | 5.2 | x | x | x | x | x | x |
| 24 | 50 | F | Ovarian ca. | Ipi + Nivo | 3.38 | 0.02 | 20.17 | 1.4 | >7.7 | 0.5 | 2.4 | 3.3 | 1.7 | x | <1 |
| 25 | 33 | F | Ovarian ca. | Ipi + Nivo | 3.63 | 0.09 | 36.76 | 1.4 | >5.9 | 2.9 | 2.4 | 3.3 | 1.7 | 53.9 | <1 |
| 26 | 67 | F | Renal cell ca. | Ipi + Nivo | 4.08 | 0.04 | 55.98 | 1.2 | 1.3 | <0.3 | 2.3 | 2.9 | 1.4 | x | x |
| 27 | 43 | F | Gastric ca. | Ipi + Nivo | 1.1 | 0.01 | x | x | >5.9 | x | x | x | x | 11.1 | <1 |
Abbreviations: M, male; F, female; B, baseline; hypo, hypothyroidism; x, not measured; TPO, thyroid peroxidase; TSI, thyroid-stimulating immunoglobulin; TSH, thyroid-stimulating hormone; free T4, free thyroxine; free T3, free triiodothyronine.